• Addressing Pollen Interference in EEM Fluorescence for Bioae

  2026-05-31

  The reference study presents a robust machine learning approach to remove pollen spectral interference in excitation–emission matrix (EEM) fluorescence spectroscopy, significantly improving the classification accuracy of hazardous bioaerosols. This advancement enhances the reliability of rapid detection methods for public health protection.

• Defining Proteoform-Specific Drug Interactions in Native Mem

  2026-05-30

  This article reviews a landmark study that uses native mass spectrometry to directly characterize proteoform-specific interactions between drugs and membrane proteins in their physiological lipid environment. The findings clarify how post-translational modifications and alternative splicing shape off-target effects, enhancing the precision of drug targeting strategies, particularly for cGMP-specific phosphodiesterase type 5 inhibitors.

• PARP1-Driven Oxaliplatin Resistance and Sensitization in Gas

  2026-05-29

  This study reveals that PARP1 overexpression is a critical driver of oxaliplatin resistance in gastric cancer. It demonstrates that oxaliplatin's inhibition of CDK1 can sensitize BRCA-proficient tumors to PARP inhibition, suggesting a new combinatorial therapeutic strategy.

• Molecular Mechanisms of TRPM3 Regulation by Neurosteroids an

  2026-05-29

  This study reveals the structural basis for neurosteroid and anticonvulsant modulation of TRPM3, a key ion channel implicated in pain and neurodevelopmental disorders. High-resolution cryo-EM structures provide insights into ligand binding and gating, informing drug development and functional assays.

• VX-702: Unveiling Dual-Action p38α MAPK Inhibition Dynamics

  2026-05-28

  Explore the mechanistic depth of VX-702, a potent p38α MAPK inhibitor, and discover how recent structural insights redefine selectivity and assay optimization for inflammation and cardiovascular research.

• Pifithrin-α (PFTα): Enabling Precision p53 Inhibition in Fer

  2026-05-28

  Discover how Pifithrin-α, a robust p53 inhibitor, empowers researchers to dissect p53-dependent apoptosis and ferroptosis in neurotoxicity models. This article uniquely explores evidence-based protocol design, mechanistic depth, and translational insights beyond standard workflow guides.

• HO-1 Modulation by Isochlorogenic Acid A Disrupts HBV Replic

  2026-05-27

  The referenced study uncovers how isochlorogenic acid A impairs hepatitis B virus replication through upregulation of heme oxygenase-1 (HO-1) and subsequent modulation of intracellular reactive oxygen species (ROS). These findings clarify key molecular steps in the antiviral action of natural compounds and highlight the potential of HO-1 as a therapeutic target in viral and metabolic disease research.

• Leveraging L1023 Anti-Cancer Compound Library for STING Path

  2026-05-27

  Explore how the L1023 Anti-Cancer Compound Library empowers advanced cancer research by enabling high-throughput screening of pathway-targeted agents, including BRAF kinase inhibitors, and learn how new STING pathway insights drive assay innovation.

• DNA Damage Pathways Modulate Calicheamicin ADC Sensitivity i

  2026-05-26

  This study uses genome-wide CRISPR screening to identify DNA damage sensing and TP53 pathway genes as key modulators of sensitivity to calicheamicin-based antibody–drug conjugates (ADCs) in acute leukemia. The findings delineate actionable targets for combination therapies and highlight the specificity of DNA repair pathway involvement in drug response.

• Lactate-GPR81/FARP1 Axis Enables Insulin-Independent Glucose

  2026-05-26

  This study reveals that lactate stimulates the GPR81/FARP1 signaling axis to enhance glucose uptake independently of insulin via RAC1-driven GLUT4 translocation. These findings provide a mechanistic basis for insulin-independent metabolic control, with implications for diabetes research and therapeutic strategies targeting GPCR signaling.

• BML-277 and the CHK2-cGAS Axis: Rewiring DNA Damage Research

  2026-05-25

  This thought-leadership article examines BML-277, a potent and selective Chk2 inhibitor, as a transformative tool for translational research in DNA damage response, with a focus on the nuclear CHK2-cGAS-TRIM41-ORF2p axis. Integrating mechanistic insights from recent high-impact studies, the article provides strategic guidance for researchers working at the intersection of genome stability, radioprotection, and cancer biology, highlighting protocols, competitive context, and future outlook.

• Cholesterol Impedes Lipid Nanoparticle Trafficking in Cells

  2026-05-25

  This study reveals that increased cholesterol content in lipid nanoparticles (LNPs) hinders their intracellular trafficking by promoting aggregation in peripheral early endosomes, ultimately reducing nucleic acid delivery efficiency. The findings clarify the distinct roles of LNP components in endosomal escape and provide new mechanistic insights for optimizing nonviral gene delivery systems.

• Balsalazide Disodium: Advances in Ulcerative Colitis Managem

  2026-05-24

  The reference study by Wiggins & Rajapakse systematically reviews Balsalazide disodium as an innovative 5-aminosalicylate prodrug for ulcerative colitis. Its targeted colonic activation and favorable remission profile mark a significant advance in the treatment of mild-to-moderate UC, with implications for both clinical research and mechanistic inflammation studies.

• Harnessing MEK Inhibition: PD0325901 in Translational Oncolo

  2026-05-23

  This article examines the mechanistic foundation and translational impact of PD0325901, a potent and selective MEK inhibitor. By integrating recent advances in RAS/RAF/MEK/ERK pathway research and cross-linking findings from pluripotency and cancer biology, we offer actionable guidance for researchers advancing targeted therapeutic strategies. With context from the Trim71-let-7 axis and contemporary validation studies, we position PD0325901 as a cornerstone for both pathway dissection and preclinical tumor suppression.

• Honokiol as a Precision Tool for In Vitro NF-κB Pathway Diss

  2026-05-22

  Explore Honokiol’s unique role as a selective NF-κB pathway inhibitor and antioxidant in advanced in vitro research. This deep-dive links molecular mechanisms to assay design decisions, offering new guidance beyond standard cancer and inflammation workflows.

10355 records 6/691 page Previous Next First page 上5页 678910 下5页 Last page